Organization
Harvard Medical School
2 clinical trials
176 abstracts
5 posters
Abstract
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.Org: Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial.Org: David Geffen School of Medicine at University of California Los Angeles, Moscow City Oncology Hospital No.62, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, National Taiwan University Hospital,
Abstract
Prior authorizations for oral anticancer drugs and delayed prescription fills.Org: Boston, MA, Harvard Medical School,
Abstract
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,
Abstract
Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).Org: HonorHealth Research Institute, Duke Cancer Institute, Chaim Sheba Medical Center, University of Cincinnati Cancer Institute, International Drug Development Institute,
Abstract
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.Org: Children’s Hospital of Philadelphia, University of Pennsylvania, Children's Oncology Group Statistics and Data Center, University of Florida, CanSino Biologics, Dana Farber Cancer Institute, Boston, MA,
Abstract
Telehealth-based psychological intervention for caregivers of patients with primary malignant brain tumors: A randomized controlled trial.Org: Massachusetts General Hospital, Harvard University, Division of Hematology & Oncology, Harvard Medical School, UMass Memorial Cancer Center,
Abstract
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.Org: Harvard Medical School, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
Associations of social determinants of health with avoidance of information, treatment receipt, and physician mistrust for women with breast cancer.Org: Dana-Farber Brigham Cancer Center, Dana-Farber Cancer Institute, Boston Medical Center, Boston University, Survey and Data Management Core,
Abstract
Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Alliance Statistics and Data Management Center, Mayo Clinic Rochester,
Abstract
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.Org: Berry Consultants, LLC, Global Coalition for Adaptive Research, Hunstman Cancer Institute at the University of Utah, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA,
Abstract
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Barts Cancer Institute,
Abstract
Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy.Org: Massachusetts General Hospital, Boston, MA, Harvard Medical School, The Ohio State University Wexner Medical Center, Columbus, OH,
Abstract
Multi-site randomized trial of stepped palliative care (PC) for patients with advanced lung cancer.Org: Massachusetts General Hospital, Division of Hematology and Oncology/Department of Medicine, Boston, MA, Harvard Medical School, University of Pennsylvania,
Abstract
Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high grade glioma.Org: Memorial Sloan Kettering Cancer Center, Harvard Medical School, Weill Cornell Medicine, NYU Langone Health, Department of Pathology and Laboratory Medicine,
Abstract
Pre-clinical modeling of navtemadlin pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in glioblastoma, IDH-wildtype.Org: Mayo Clinic, University of Minnesota, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.Org: Yale University School of Medicine and Yale Cancer Center, Dana Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Johns Hopkins University, University of Pennsylvania Medical Center, University of Maryland Marlene and Stewart Greenebaum Cancer Center,
Abstract
Prospective validation of ctHPVDNA for detection of minimal residual disease and prediction of recurrence in patients with HPV-associated head and neck cancer treated with surgery.Org: Harvard Medical School, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Massachusetts General Hospital, Mass Eye and Ear/Mass Gen Hospital, Harvard University,
Abstract
Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC.Org: Onc.AI, Pfizer Inc., Department of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital,
Abstract
Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.Org: Massachusetts General Hospital Cancer Center, Northwestern Memorial Hospital, Chicago, IL, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Massachusetts General Hospital,
Abstract
H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).Org: Royal Marsden NHS Foundation Trust, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarah Cannon Research Institute/Tennessee Oncology, Eisai,
Abstract
Novel epigenomic liquid biopsy assay to predict estrogen receptor (ER) status and to infer ER pathway activation in breast cancer.Org: Dana-Farber Cancer Institute, Precede Biosciences, Harvard Medical School,
Abstract
Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).Org: Guardant Health, Inc., Guardant Health, Sarah Cannon Research Institute/Tennessee Oncology, Winship Cancer Institute of Emory University, Massachusetts General Hospital Cancer Center,
Abstract
Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.Org: David Geffen School of Medicine at UCLA, University of California Irvine, Jonsson Comprehensive Cancer Center, Los Angeles, CA, Gilead Sciences, Inc.,
Abstract
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.Org: Dana-Farber Cancer Institute, Yale School of Medicine, University of Pittsburgh Medical Center (UPMC), Yale Cancer Center, Harvard Medical School,
Abstract
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Dana-Farber Cancer Institute, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Immune related adverse events in patients with breast cancer and autoimmune disease treated with immunotherapy.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Department of Radiation Oncology, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
CREB5 as an essential transcription and tumorigenic regulator in basal-like breast and prostate cancer.Org: University of Minnesota, Rush University Medical College, Harvard Medical School, University of Minnesota Masonic Cancer Center,
Abstract
Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-institutional study.Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Massachusetts General Hospital, Harvard Medical School, Washington University in St. Louis, Natera, Inc.,
Abstract
The landscape of the intestinal microbiome amongst patients with newly diagnosed invasive breast cancer (BC) and ductal carcinoma in situ (DCIS).Org: Dana-Farber Cancer Institute, Department of Biostatistics & Data Science, Microbiome Analysis Core, Harvard T.H. Chan School of Public Health, Harvard Medical School,
Abstract
Nectin-4 expression in primary breast cancer and associated clinical outcomes.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Broad Institute of Harvard and MIT, Massachusetts General Hospital, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, DFCI/PCC Fellowship Program - Attendings, Personalis, Inc.,
Abstract
Survival outcomes and treatment patterns by tumor subtype (TS) in stage III inflammatory and non-inflammatory breast cancer (BC).Org: Dana-Farber Cancer Institute/Harvard Medical School, Grupo Oncológico Cooperativo del Sur, Brigham and Women's Hospital, Tufts Medical Center/Tufts University, Michigan State University,
Abstract
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Winship Cancer Institute of Emory University, Seoul National University Hospital, IRCCS Ospedale San Raffaele,
Abstract
Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in a cell-free DNA or tumor tissue genotyping assay.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, The University of Texas MD Anderson Cancer Center, Emory University School of Medicine, Massachusetts General Hospital,
Abstract
The oncology care model and initiation of systemic therapy for cancer.Org: Harvard Medical School, Brigham and Women's Hospital, Department of Health Care Policy, Dana-Farber Cancer Institute, Dartmouth Cancer Center, Lebanon, NH,
Abstract
Post-acute care facility utilization and outcomes among Medicare beneficiaries undergoing inpatient cancer surgery.Org: Massachusetts General Hospital, Harvard Medical School, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Dana-Farber Cancer Institute,
Abstract
Impact of clinical response and AEs on health-related quality of life (HRQoL) in patients (pts) with R/R large B-cell lymphoma (LBCL): Pooled data from 4 lisocabtagene maraleucel (liso-cel) trials.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Evidera PPD, Bethesda, Bristol Myers Squibb,
Abstract
Relationship between cognitive and emotional domains of prognostic awareness with quality of life and psychological distress in patients with advanced cancer.Org: The Warren Alpert Medical School of Brown University, University of Massachusetts Chan Medical School, Massachusetts General Hospital, Harvard Medical School, Brigham and Women’s Hospital,
Abstract
Potentially inappropriate medications and their association with frailty, unplanned hospitalizations, and mortality in patients with cancer treated in the national U.S. Veterans Affairs Healthcare System.Org: VA Boston Healthcare System, Brigham and Women's Hospital, VA Greater Los Angeles Healthcare System, Massachusetts Veterans Epidemiology Research and Information Center, Harvard Medical School,
Abstract
Barriers to accrual and enrollment in brain tumor trials.Org: Dana-Farber Cancer Institute, Massachusetts General Hospital, University of California Irvine, The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center School of Nursing,
Abstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, UNC Lineberger Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Emory University Hospital,
Abstract
Shareable artificial intelligence to extract cancer outcomes from electronic health records.Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Dana-Farber Cancer Institute, Boston, MA, USA, Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, Dana-Farber Cancer Institute, Boston, MA, Dana-Farber Cancer Institute,
Abstract
Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.Org: Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Michigan, University of Chicago, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Division of Hematology and Oncology,
Abstract
Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.Org: Baylor University Medical Center, Texas Oncology, The US Oncology Network, International Breast Cancer Center (IBCC), Quironsalud Group,
Abstract
INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC).Org: Genentech, Product Development Data Science, F. Hoffmann-La Roche Ltd., F. Hoffmann-La Roche Ltd, Roche Products Ltd., Product Development Oncology, F. Hoffmann-La Roche Ltd.,
Abstract
Detection of immune-related adverse events among hospitalized patients using large language models.Org: Harvard Medical School, Massachusetts General Hospital, Brigham and Women's Hospital/Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Oregon Health and Science University,
Abstract
H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Royal Marsden NHS Foundation Trust, Lineberger Comprehensive Cancer Center,
Abstract
Breast cancer disparities among Hispanics in the US: Insights into healthcare access.Org: Beth Israel Deaconess Medical Center, Harvard Medical School, Tufts Medical Center/Tufts University,
Abstract
Two years of teaching close to home: Lessons learned from a near-peer model for an introductory lecture series for hematology-oncology fellows.Org: Beth Israel Deaconess Medical Center, Harvard Medical School,
Abstract
Impact of tertiary lymphoid structures in response to immune checkpoint blockade in patients with head and neck squamous cell carcinoma.Org: Massachusetts General Hospital, Harvard Medical School, Center for Head and Neck Cancers, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA,
Abstract
Genomic evolution of patients with myeloid neoplasms and known antecedent clonal hematopoiesis.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Leukemia, H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute,
Abstract
Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC).Org: Dana-Farber Cancer Institute, Guardant Health Inc., Brigham and Women's Hospital/Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital,
Abstract
Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, DFCI/PCC Fellowship Program - Attendings, Yale Cancer Center,
Abstract
Classification of HER2 status across multiple cancers using epigenomic profiles from a novel liquid biopsy assay.Org: Precede Biosciences, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings,
Abstract
Coping in caregivers of patients with primary malignant brain tumors: A mediation analysis of a randomized controlled trial.Org: Massachusetts General Hospital, Harvard Medical School, Harvard University,
Abstract
The association between osimertinib and nutritional deficiency among patients with non-small cell lung cancer.Org: Unity Hospital, Rochester Regional Health System, Mount Auburn Hospital, Harvard Medical School, Cambridge University Hospitals NHS Foundation Trust,
Abstract
Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma.Org: Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Safety and efficacy of interleukin-6 blockade for immune-related adverse events: A systematic review and meta-analysis.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, University of Toronto,
Abstract
Development of a highly efficacious, first-in-class antibody-drug conjugate against a novel MUC1-C oncoprotein for metastatic colorectal cancer.Org: XYone Therapeutics, BWH, Harvard Medical School,
Abstract
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, UPMC Hillman Cancer Center, NSABP Foundation, Inc. Pathology Lab,
Abstract
Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).Org: Dana-Farber Cancer Institute, Harvard Medical School, Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Mayo Clinic Florida,
Abstract
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).Org: NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, NSABP Foundation, Inc., UPMC Hillman Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
Abstract
The effect of sodium glucose cotransporter-2 inhibitors on mortality and cardiovascular outcomes of patients with prostate cancer receiving luteinizing hormone releasing hormone agonists.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Unity Hospital, Rochester Regional Health System, Rochester, NY, Mount Auburn Hospital,
Abstract
Investigation of T cell phenotypes associated with response or resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC).Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine, Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, The Lank Center for Genitourinary Oncology,
Abstract
Direct oral anticoagulant versus low molecular weight heparin for venous thromboembolism in patients receiving immune checkpoint inhibitors.Org: Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, Department of Medicine, Icahn School of Medicine at Mount Sinai, Danbury Hospital,
Abstract
Survival in de novo metastatic merkel cell carcinoma according to sites of metastases.Org: Dana-Farber Cancer Institute, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA, Harvard Medical School,
Clinical trial
Improving Outcomes in Depression in Primary Care in a Low Resource Setting: Evidence From a Pilot StudyStatus: Completed, Estimated PCD: 2024-03-10
Clinical trial
Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens Through Improved Epidemiologic MethodsStatus: Recruiting, Estimated PCD: 2026-06-30
Abstract
Impact of the oncology care model (OCM) on Medicare payments, utilization, and care delivery: Update through year 5.Org: Dartmouth Cancer Center, Lebanon, NH, Abt Associates, Department of Health Care Policy, The Lewin Group, GDIT,
Abstract
Developing machine learning algorithms incorporating patient reported outcome measures to predict acute care events among patients with cancer.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Massachusetts General Hospital, Harvard Medical School,
Abstract
A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.Org: Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, Department of Data Sciences, Dana-Farber Cancer Institute,
Abstract
Quality and accessibility of liquid biopsy information: An analysis of online content.Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Dana-Farber Cancer Institute, Harvard Medical School, University of California San Francisco,
Abstract
Belzutifan treatment of Von Hippel-Lindau (VHL) related central nervous system (CNS) hemangioblastomas (HBs): A single institution experience.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Massachusetts General Hospital, Massachusetts General Hospital Harvard Medical School,
Abstract
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.Org: Dana-Farber Cancer Institute, Mayo Clinic, Harvard Medical School, Brigham and Women's Hospital/Massachusetts General Hospital, National Cancer Institute, Vilnius, Lithuania,
Abstract
Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Boston, MA, Stephenson Cancer Center University of Oklahoma/Sarah Cannon Research Institute, Oklahoma City, OK,
Abstract
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer.Org: Harvard Radiation Oncology Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Should I stay, or should I go? Factors associated with intent to leave academic oncology.Org: University of California San Francisco, University of Utah, Dana-Farber Cancer Institute, Harvard Medical School, Memorial Sloan Kettering Cancer Center,
Abstract
Association between inpatient clinical nursing acuity and 30-day rehospitalization among hospitalized patients with advanced cancer.Org: Massachusetts General Hospital, Harvard Medical School, University of Oklahoma Stephenson Cancer Center,
Abstract
Neoadjuvant giredestrant + palbociclib (P) vs. anastrozole (A) + P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2– eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study.Org: Samsung Medical Center, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, University Hospital Erlangen, Comprehensive Cancer Center (CCC) Erlangen-EMN, Friedrich-Alexander University Erlangen-Nürnberg,
Abstract
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).Org: Medical Oncology Group, Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA,
Abstract
Association of pretreatment chest CT abnormalities with trastuzumab deruxtecan–associated pneumonitis.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Dana-Farber Cancer Institute,
Abstract
Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.Org: Dana-Farber Cancer Institute, Harvard Medical School, Inova Schar Cancer Institute, Instituto Valenciano de Oncología, Princess Margaret Cancer Centre,
Abstract
AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,
Abstract
Deep learning to estimate RECIST in cancer patients treated in real-world settings.Org: Dana-Farber Cancer Institute, Harvard Medical School, Massachusetts General Hospital,
Abstract
Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.Org: Perelman School of Medicine, University of Pennsylvania, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center,
Abstract
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Guardant Health, Inc., Palo Alto, CA, Redwood City, CA,
Abstract
The impact of renin-angiotensin-aldosterone system inhibitors on immune checkpoint inhibitor-associated adverse cardiovascular events.Org: National Taiwan University Hospital Yunlin Branch, Mount Auburn Hospital, Harvard Medical School, Cambridge University Hospitals NHS Foundation Trust, Taipei TzuChi Hospital,
Abstract
Characterization of the immunophenotype and tumor specificity of CD8+ T-cells in chromophobe renal cell carcinoma (ChRCC) and renal oncocytic neoplasms.Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, St. Elizabeth's Medical Center, Brighton, MA,
Abstract
MTHFR polymorphisms and neurotoxicity and overall survival after methotrexate-based therapy in primary CNS lymphoma.Org: Ludwig-Maximilians-University, University of Tuebingen, Massachusetts General Hospital, Harvard Medical School, Brigham and Woman’s Hospital,
Abstract
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).Org: University of Texas MD Anderson Cancer Center, University of Pittsburgh, Pittsburgh, PA, NRG Oncology SDMC, UPMC Hillman Cancer Center, NSABP Foundation,
Abstract
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable pancreatic adenocarcinoma.Org: Harvard Radiation Oncology Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Assessing tumor-infiltrating immune cells and outcomes with cisplatin- versus carboplatin-based treatment in advanced urothelial cancer (UC): Survival analysis of three platinum-treated UC cohorts.Org: Medical University of Lodz, Lodz, Poland, PSMAR Hospital del Mar Medical Research Institute (IMIM), Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Dana-Farber Cancer Institute,
Abstract
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Guardant Health, Inc., Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, Department of Data Sciences, Winship Cancer Institute of Emory University,
Abstract
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.Org: Clinical Care Options, LLC, Reston, VA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Henry Ford Cancer Institute, Detroit, MI, University of Colorado Denver Anschutz Medical Center, Dana-Farber Cancer Institute,
Abstract
Kidney cancer mortality in the United States between 1999 and 2020: An observational analysis of outcomes by gender, race, and ethnicity.Org: Cleveland Clinc, Mount Auburn Hospital, Harvard Medical School, Case Western Reserve University School of Medicine, University of California San Diego,
Abstract
A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.Org: Massachusetts Eye and Ear Infirmary, Harvard Medical School, Northshore University Healthsystem, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
ARC-20: A phase 1 dose-escalation and dose-expansion study to investigate the safety, tolerability, and pharmacology of HIF-2α inhibitor AB521 monotherapy in patients with clear cell renal cell carcinoma and other solid tumors.Org: Dana Farber Cancer Institute, Boston, MA, Harvard Medical School, Sarah Cannon Research Institute/Tennessee Oncology, Arcus Biosciences, Nebraska Cancer Specialists,
Abstract
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).Org: Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, MRC Clinical Trials Unit at UCL, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, SWOG Statistical Center,
Abstract
The impact of sodium-glucose cotransporter-2 inhibitors on the outcome of patients with colorectal adenocarcinoma.Org: Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, National Taiwan University Hospital Yunlin Branch, Taipei, Taiwan,
Abstract
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alliance Statistics and Data Center, Mayo Clinic, University of North Carolina at Chapel Hill,
Abstract
Characterizing telomerase reverse transcriptase (TERT) promoter mutations (mut) across sex, race, and cancer types.Org: Dana-Farber Cancer Institute, Harvard Medical School, Lebanese University, Faculty of Medical Sciences, Department of Data Sciences,
Abstract
Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.Org: Medical Oncology Group, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Boston, MA, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.Org: University of Texas MD Anderson Cancer Center, The University of Pittsburgh, NRG Oncology SDMC, NSABP Foundation, Inc., UMPC Hillman Cancer Center,
Abstract
Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.Org: Harvard Medical School, Dana-Farber Cancer Institute, Children’s Mercy Hospitals and Clinics,
Abstract
Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC).Org: Harvard Medical School, Massachusetts General Hospital, Boston, MA, MD Anderson Cancer Center, Houston, TX,
Abstract
Race and ethnicity reporting by US federal standards in high-impact phase 2/3 oncology clinical trial publications.Org: Stanford Cancer Institute, Harvard Medical School, University of California San Francisco School of Medicine, Harvard University, Tulane University School of Medicine,
Abstract
Sexual dysfunction in women with lung cancer: Updates from the SHAWL study.Org: Dana-Farber Cancer Institute, Harvard Medical School, University of California San Francisco, Brigham and Women's Hospital/Massachusetts General Hospital, Rush University Medical Center,
Abstract
Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, City of Hope Comprehensive Cancer Center, Centro de Cancer de Brasilia, Instituto Unity de Ensino e Pesquisa, Grupo Oncoclinicas,
Abstract
Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Harvard Medical School, Yale University,
Abstract
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Winship Cancer Center of Emory University, Seoul National University Hospital, Cancer Research Institute,
Abstract
Association of host immune signatures with response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC).Org: Dana-Farber Cancer Institute, Harvard Medical School, Dartmouth College Geisel School of Medicine, Brigham and Women's Hospital/Massachusetts General Hospital, School of Medicine, Yale University, New Haven, CT,
Abstract
Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.Org: Kura Oncology, Massachusetts General Hospital, Harvard Medical School, Department of Leukemia, Roswell Park Comprehensive Cancer Center,
Abstract
A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myoinvasive bladder cancer.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Brigham and Women’s Hospital, Harvard Medical School, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, University of California Davis Comprehensive Cancer Center,
Abstract
Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) –based regimens.Org: Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
Exercise to enhance cardiovascular health among Black patients with prostate cancer with androgen deprivation therapy: The POWER trial.Org: Dana-Farber Cancer Institute, Boston, MA, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard T. H. Chan School of Public Health,
Abstract
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).Org: University of Texas MD Anderson Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: Medical College of Wisconsin, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, University Hospitals Seidman Cancer Center,
Abstract
Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, CHU de Poitiers, Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers, Pôle Régional de Cancérologie,
Abstract
Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, MD Anderson Hematology/Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia.Org: Massachusetts General Hospital, Harvard Medical School, Oryzon Genomics, Cornella De Llobregat, Barcelona Clinic Liver Cancer,
Abstract
Selection biases in the systematic collection of breast biobank specimens.Org: Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School,
Abstract
Racial disparities in survival and stage at diagnosis among adolescent and young adult patients with cancer.Org: Stanford Cancer Institute, Harvard University, Harvard Medical School, Columbia University Medical Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Abstract
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Medicine, Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Harvard Medical School, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Disparity in regional recruitment across global cancer trials: A meta-analysis.Org: Creighton University School of Medicine Phoenix Regional Campus, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic, Fatima Jinnah Medical University, University of Arizona,
Abstract
Exploring decisional control preferences in older patients with cancer and their caregivers.Org: University of Rochester Medical School, Brigham and Women’s Hospital, Harvard Medical School, Wilmot Cancer Institute, University of Rochester Medical Center,
Abstract
PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study.Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Institute for Clinical and Translational Research, Baylor College of Medicine, Baylor College of Medicine, Children's Oncology Group,
Abstract
Characterizing the digital divide in a diverse cohort of African American (AA) patients (pts) with prostate cancer (PCa).Org: Dana-Farber Cancer Institute, Brigham and Women's Hospital/Massachusetts General Hospital, Emory University School of Medicine, Division of Urological Surgery and the Center for Surgery and Public Health, Harvard Medical School,
Abstract
Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Dana-Farber Cancer Institute, Harvard Medical School, University Hospital Essen,
Abstract
Effect of the COVID-19 pandemic on radical prostatectomy: A Brazilian retrospective study.Org: Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, Federal University of Piaui, Teresina, Brazil, Dana-Farber Cancer Institute,
Abstract
Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.Org: Sorbonne University and Saint-Antoine Hospital, Hôpital Saint-Antoine, INSERM UMRs938, Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics,
Abstract
What is your preferred language? Evaluating equal access to oncology clinical studies for non-English-speaking participants.Org: Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital/Massachusetts General Hospital, Dartmouth-Hitchcock Cancer Center, Stanford University School of Medicine,
Abstract
Association of KMT2C loss-of-function mutations in circulating tumor DNA and prolonged response to the combination of PARPi and PI3Ki.Org: Mayo Clinic, Beth Israel Deaconess Medical Center, Harvard Medical School, Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute,
Abstract
Analysis and optimization of equitable US cancer clinical trial center access by travel time.Org: Cold Spring Harbor Laboratory, Department of Neurobiology and Howard Hughes Medical Institute, Harvard Medical School, University of Warwick, The George Washington University School of Medicine and Health Sciences,
Abstract
Characterizing imposter syndrome among oncologists on social media.Org: Valley Health System, Paramus, NJ, Medical College of Wisconsin, Milwaukee, WI, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI,
Abstract
Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Columbia University Irving Medical Center, New York, NY, USA, New York, NY,
Abstract
A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.Org: Memorial Sloan Kettering Cancer Center, Institute for Clinical and Translational Research, Baylor College of Medicine, Baylor College of Medicine, Children's Oncology Group, Mayo Clinic,
Abstract
The impact of large oncology meetings (#ASCO, #AACR, #ASH) and health equity hashtags (#DEI+) on social media engagement.Org: Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Rhode Island Hospital, Dana-Farber Cancer Institute, Harvard Medical School, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
The efficacy of cationic amphiphilic antihistamines on outcomes of patients with pancreatic ductal adenocarcinoma.Org: Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, National Taiwan University Hospital Yunlin Branch, Taipei, Taiwan,
Abstract
The timing of statin initiation on survival outcomes of cancer patients treated with immune checkpoint inhibitors: A retrospective cohort study.Org: Unity Hospital, Rochester Regional Health System, Department of Medical Education, Kuang Tien General Hospital, Mount Auburn Hospital,
Abstract
Plasma KIM-1 for preoperative prediction of renal cell carcinoma versus benign renal masses, and association with clinical outcomes.Org: Dana-Farber Cancer Institute, N.N. Blokhin National Medical Research Centre of Oncology, International Agency for Research on Cancer, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
Clinical performance of Bladder EpiCheck methylation test for active surveillance of non-muscle invasive bladder cancer: Systematic review and meta-analysis.Org: Taipei TzuChi Hospital, Department of Medical Education, Kuang Tien General Hospital, Mount Auburn Hospital, Harvard Medical School,
Abstract
PAVING the path to wellness: Lifestyle medicine to improve outcomes in breast cancer survivors.Org: Massachusetts General Hospital, Harvard Medical School, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Metropolitan State University of Denver,
Abstract
Obesity, dyslipidemia, and diabetes as determinants of response to immune checkpoint inhibitors in non-small cell lung cancer.Org: Beth Israel Deaconess Medical Center, Roswell Park Comprehensive Cancer Center, Mount Auburn Hospital, Harvard Medical School, Lahey Hospital and Medical Center, Burlington, MA,
Abstract
“It’s been a long journey:” A qualitative study of patient and caregiver experiences during multimodality treatment for locally advanced rectal cancer.Org: Massachusetts General Hospital, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Harvard Medical School, University of Oklahoma Stephenson Cancer Center,
Abstract
Cost of care associated with utilization of telehealth in clinical trials.Org: University of Pennsylvania Perelman School of Medicine, University of Pennsylvania, Division of Gynecologic Oncology, University of Pennsylvania, Harvard Medical School, Division of Urogynecology,
Abstract
Risk factors, clinical characteristics, and treatment outcomes for hepatocellular carcinoma in Rwanda.Org: University of Illinois at Chicago College of Medicine, Division of Medical Oncology, University of Rwanda, College of Medicine and Health Sciences, United Arab Emirates University, Alain, United Arab Emirates, King Faisal Hospital (KFH), University Teaching Hospital of Kigali (CHUK),
Abstract
An estimate of the burden of pancreatic cancer globally and its comparison with different WHO regions using Global Burden of Disease Database: A retrospective population-based analysis.Org: Mount Auburn Hospital, Harvard Medical School, Department of Medicine, Icahn School of Medicine at Mount Sinai, Froedtert and Medical College of Wisconsin, University of Oxford,
Abstract
Trajectories of physical well-being among adults with acute myeloid leukemia.Org: James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, University of Rocheser Medical Center, Department of Psychiatry and Human Behavior, University of California, Irvine,
Abstract
Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary to in-transit and distant metastasis in acral melanoma.Org: Dana-Farber Cancer Institute, Universitatsklinikum Essen Klinik fur Dermatologie, Laboratory of Systems Pharmacology, Harvard Medical School, Department of Applied Computational Cancer Research,
Abstract
Comparison of response from RECIST1.1 and abstraction in real-world patients with lung cancer.Org: Genentech, Inc., Brigham and Women’s Hospital, Harvard Medical School, F. Hoffmann-La Roche Ltd,
Abstract
18F-FDG PET and CT identifiers of high-risk lesions in the stomach and esophagus.Org: Massachusetts General Hospital, Harvard Medical School,
Abstract
Sarcopenia vs body mass index (BMI) as a prognostic biomarker in patients with metastatic clear cell renal cell carcinoma (mCCRCC) in the era of first line immune checkpoint inhibitors (ICIs).Org: University of Washington School of Medicine, Vanderbilt University Medical Center, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Emory University, Atlanta, GA, USA,
Abstract
A dual institution real-world study of avelumab for advanced Merkel cell carcinoma.Org: Massachusetts General Hospital, Massachusetts Eye and Ear, Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
AI-based pathologic biomarker for pathologic downstaging in patients with muscle-invasive bladder cancer undergoing cystectomy after neoadjuvant nivolumab, gemcitabine, and cisplatin: BLAAST-1 Trial.Org: Valar Labs, Inc., Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Huntsman Cancer Institute, Hunstman Cancer Institute at the University of Utah,
Abstract
Falls and hospitalization during chemotherapy in older women with early breast cancer.Org: City of Hope National Medical Center, Duarte, CA, University of Nebraska Medical Center, Omaha NE, Neurocentria,
Abstract
Association of immune-related adverse events and improved treatment outcomes across race/ethnicity in a diverse patient population.Org: Mount Auburn Hospital, Harvard Medical School, St. Elizabeth's Medical Center, Boston University School of Public Health, Boston University Medical Center,
Abstract
Impact of the Covid-19 pandemic on the treatment of resectable liver neoplasms: A cross-sectional study from Brazil.Org: Faculdade de Medicina da Universidade de São Paulo, Federal University of Piaui, Dana-Farber Cancer Institute, Harvard Medical School, Universidade de Santa Cruz do Sul,
Abstract
Implementation of a housing insecurity screening tool in patients with lung cancer.Org: Boston University Medical Center, Mount Auburn Hospital, Harvard Medical School, Boston University Section of Hematology and Medical Oncology, Boston University School of Public Health,
Abstract
Age-standardized incidence, mortality rates, mortality-to-incidence ratios, and disability-adjusted life years for acute lymphoblastic leukemia in the European Union 15 + countries, Australia, and United States of America.Org: Mercy Catholic Medical Center, Lansdowne, PA, Mount Auburn Hospital, Harvard Medical School, Landmark Medical Center, Landmark Medical Hospital,
Abstract
Efficacy and safety of dose-escalated alectinib in patients with metastatic ALK-positive NSCLC and CNS relapse on standard dose alectinib.Org: Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School,
Abstract
Hyperinsulinemia and risk of lethal prostate cancer.Org: Harvard Medical School, Harvard T.H. Chan School of Public Health,
Abstract
A supervised remote exercising program for patients receiving immunotherapy alone or in combination with chemotherapy in Brazil: ExIO.Org: Centro de Cancer de Brasilia, Instituto Unity de Ensino e Pesquisa, Grupo Oncoclinicas, Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Hospital Universitario de Brasilia,
Abstract
Pilot randomized trial of a telehealth intervention for women with advanced ovarian cancer and PARP inhibitor-related fatigue.Org: Dana-Farber Cancer Institute, University of Colorado Anschutz Medical Campus, Harvard Medical School, University of Colorado Boulder, University of Pennsylvania,
Abstract
Understanding and preparing for life on immunotherapy (UPLIFT): A feasibility randomized controlled trial among adults with advanced cancer.Org: Massachusetts General Hospital, Harvard Medical School,
Abstract
The impact of cationic amphiphilic antihistamines on patients with lung cancer receiving immunotherapy.Org: National Taiwan University Hospital Yunlin Branch, Mount Auburn Hospital, Harvard Medical School, Unity Hospital, Rochester Regional Health System,
Abstract
ASSOCIATION OF FRAILTY WITH ADVERSE OUTCOMES IN SLEOrg: Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University,
Abstract
A NOVEL BLOOD-BASED ASSAY DIFFERENTIATES SEROPOSITIVE AND SERONEGATIVE RHEUMATOID ARTHRITIS WITH HIGH SENSITIVITY AND SPECIFICITY FROM HEALTHY INDIVIDUALS AND THOSE WITH OTHER INFLAMMATORY DISEASES OR OSTEOARTHRITISOrg: Aqtual Inc., Botnar Research Centre, Brigham and Women’s Hospital, Harvard Medical School,
Abstract
ASSOCIATION BETWEEN CHANGE IN HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX AND TREATMENT RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN TOCILIZUMAB CLINICAL TRIALSOrg: Massachusetts General Hospital, Harvard Medical School, Genentech,
Abstract
A PHASE I PHARMACOKINETICS TRIAL COMPARING PF-06438179 (A POTENTIAL BIOSIMILAR) AND INFLIXIMAB IN HEALTHY VOLUNTEERS (REFLECTIONS B537-01) Org: Pfizer Inc., London, United Kingdom, Sanofi-Aventis, Google Research, Harvard Medical School, Microsoft Research,
Abstract
An Analysis of Fatigue in Patients With Psoriatic Disease Utilizing SF-36 Vitality Scores: Results Through Week 24 in Phase 3 Trials of Guselkumab in Patients With Psoriasis and Psoriatic ArthritisOrg: Harvard Medical School, Brigham and Women’s Hospital, Department of Dermatology, Janssen Global Services, LLC, Department of Immunology and Oncology, Clínica Universidad de Navarra,
Abstract
ANTI-RHEUMATIC TREATMENT IS NOT ASSOCIATED WITH REDUCTION OF PENTRAXIN 3 (PTX3) IN RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) AND ANKYLOSING SPONDYLITIS (AS) Org: Department of medical biochemistry, Lillehammer Hospital Trust, Lillehammer Hospital for rheumatic diseases, Lillehammer, Norway, Oslo University Hospital Ullevål and Institute of Clinical Sciences, Medical biochemistry, Oslo University Hospital, Ullevål, Health science, Oslo and Akershus University College, Oslo, Norway,
Abstract
BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALSOrg: Harvard Medical School, Brigham and Women’s Hospital, The Icahn School of Medicine at Mount Sinai, Nagoya City University Graduate School of Medical Sciences, Hospital Universitari Germans Trias i Pujol,
Abstract
BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDYOrg: UCB Pharma, ASST Gaetano Pini-CTO, Dept of Rheumatology, Milan, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development, Centre for Therapeutic Innovation, University of Bath,